技术资料
-
Yates F et al. (DEC 2002) Blood 100 12 3942--9
Gene therapy of RAG-2-/- mice: sustained correction of the immunodeficiency.
Patients with mutations of either RAG-1 or RAG-2 genes suffer from severe combined immunodeficiency (SCID) characterized by the lack of T and B lymphocytes. The only curative treatment today consists of hematopoietic stem cell (HSC) transplantation,which is only partially successful in the absence of an HLA genoidentical donor,thus justifying research to find an alternative therapeutic approach. To this end,RAG-2-deficient mice were used to test whether retrovirally mediated ex vivo gene transfer into HSCs could provide long-term correction of the immunologic deficiency. Murine RAG-2-/-Sca-1(+) selected bone marrow cells were transduced with a modified Moloney leukemia virus (MLV)-based MND (myeloproliferative sarcoma virus enhancer,negative control region deleted,dl587rev primer-binding site substituted) retroviral vector containing the RAG-2 cDNA and transplanted into RAG-2-/- sublethally irradiated mice (3Gy). Two months later,T- and B-cell development was achieved in all mice. Diverse repertoire of T cells as well as proliferative capacity in the presence of mitogens,allogeneic cells,and keyhole limpet hemocyanin (KLH) were shown. B-cell function as shown by serum Ig levels and antibody response to a challenge by KLH also developed. Lymphoid subsets and function were shown to be stable over a one-year period without evidence of any detectable toxicity. Noteworthy,a selective advantage for transduced lymphoid cells was evidenced by comparative provirus quantification in lymphoid and myeloid lineages. Altogether,this study demonstrates the efficiency of ex vivo RAG-2 gene transfer in HSCs to correct the immune deficiency of RAG-2-/- mice,constituting a significant step toward clinical application. View Publication产品号#:
09600
09650
产品名:
StemSpan™ SFEM
StemSpan™ SFEM
-
Smith KS et al. (NOV 2002) Molecular and cellular biology 22 21 7678--87
Transformation of bone marrow B-cell progenitors by E2a-Hlf requires coexpression of Bcl-2.
The chimeric transcription factor E2a-Hlf is an oncoprotein associated with a subset of acute lymphoblastic leukemias of early B-lineage derivation. We employed a retroviral transduction-transplantation approach to evaluate the oncogenic effects of E2a-Hlf on murine B-cell progenitors harvested from adult bone marrow. Expression of E2a-Hlf induced short-lived clusters of primary hematopoietic cells but no long-term growth on preformed bone marrow stromal cell layers comprised of the AC6.21 cell line. Coexpression with Bcl-2,however,resulted in the sustained self-renewal of early preB-I cells that required stromal and interleukin-7 (IL-7) support for growth in vitro. Immortalized cells were unable to induce leukemias after transplantation into nonirradiated syngeneic hosts,unlike the leukemic properties and cytokine independence of preB-I cells transformed by p190(Bcr-Abl) under identical in vitro conditions. However,bone marrow cells expressing E2a-Hlf in combination with Bcl-2,but not E2a-Hlf alone,induced leukemias in irradiated recipients with long latencies,demonstrating both a requirement for suppression of apoptosis and the need for further secondary mutations in leukemia pathogenesis. Coexpression of IL-7 substituted for Bcl-2 to induce the in vitro growth of pre-B cells expressing E2a-Hlf,but leukemic conversion required additional abrogation of undefined stromal requirements and was associated with alterations in the Arf/Mdm2/p53 pathway. Thus,E2a-Hlf enhances the self-renewal of bone marrow B-cell progenitors without inciting a p53 tumor surveillance response or abrogating stromal and cytokine requirements for growth,which are nevertheless abrogated during progression to a leukemogenic phenotype. View Publication产品号#:
03134
产品名:
MethoCult™M3134
-
Montecino-Rodriguez E et al. (JAN 2001) Nature immunology 2 1 83--8
Bipotential B-macrophage progenitors are present in adult bone marrow.
According to the current model of adult hematopoiesis,differentiation of pluripotential hematopoietic stem cells into common myeloid- and lymphoid-committed progenitors establishes an early separation between the myeloid and lymphoid lineages. This report describes a rare and previously unidentified CD45R-CD19+ B cell progenitor population in postnatal bone marrow that can also generate macrophages. In addition to the definition of this B-lineage intermediate,the data indicate that a developmental relationship between the B and macrophage lineages is retained during postnatal hematopoiesis. View Publication产品号#:
04100
产品名:
MethoCult™ H4100
过滤器
筛选结果
细胞类型
- B 细胞 212 项目
- CD4+ 3 项目
- CD4+ T细胞 131 项目
- CD8+ 3 项目
- CD8+ T细胞 107 项目
- CHO细胞 15 项目
- HEK-293细胞(人胚肾293细胞) 2 项目
- NK 细胞 160 项目
- PSC衍生 32 项目
- T 细胞 384 项目
- 上皮细胞 142 项目
- 中胚层 3 项目
- 乳腺细胞 91 项目
- 先天性淋巴细胞 30 项目
- 全血 15 项目
- 其他细胞系 10 项目
- 内皮细胞 7 项目
- 内胚层 2 项目
- 前列腺细胞 18 项目
- 单个核细胞 88 项目
- 单核细胞 168 项目
- 多发性骨髓瘤细胞 6 项目
- 多能干细胞 1895 项目
- 小胶质细胞 13 项目
- 巨噬细胞 42 项目
- 巨核细胞 10 项目
- 心肌细胞 19 项目
- 成骨细胞 10 项目
- 星形胶质细胞 14 项目
- 杂交瘤细胞 91 项目
- 树突状细胞(DCs) 114 项目
- 淋巴细胞 72 项目
- 癌细胞及细胞系 149 项目
- 白细胞 27 项目
- 白细胞单采样本 16 项目
- 白血病/淋巴瘤细胞 15 项目
- 监管 1 项目
- 真皮细胞 3 项目
- 神经元 1 项目
- 神经干/祖细胞 444 项目
- 神经细胞 9 项目
- 粒细胞及其亚群 88 项目
- 红系细胞 12 项目
- 红细胞 13 项目
- 肌源干/祖细胞 11 项目
- 肝细胞 37 项目
- 肠道细胞 103 项目
- 肾细胞 4 项目
- 肿瘤细胞 28 项目
- 胰腺细胞 17 项目
- 脂肪细胞 6 项目
- 脑肿瘤干细胞 103 项目
- 血小板 4 项目
- 血管生成细胞 1 项目
- 角质形成细胞 1 项目
- 软骨细胞 9 项目
- 造血干/祖细胞 904 项目
- 造血干祖细胞 3 项目
- 造血细胞 1 项目
- 间充质基质细胞 26 项目
- 间充质干/祖细胞 148 项目
- 间充质干祖细胞 1 项目
- 骨髓基质细胞 2 项目
- 骨髓间质细胞 1 项目
- 髓系细胞 134 项目
- 肾脏细胞 8 项目
- CD4+T细胞 1 项目
- CD8+T细胞 1 项目
- PSC衍生上皮细胞 48 项目
- PSC衍生中胚层 29 项目
- PSC衍生内皮细胞 27 项目
- PSC衍生内胚层 32 项目
- PSC衍生心肌细胞 32 项目
- PSC衍生神经细胞 139 项目
- PSC衍生肝细胞 24 项目
- PSC衍生造血干细胞 47 项目
- PSC衍生间充质细胞 32 项目
- 其他T细胞亚型 31 项目
- 呼吸道细胞 101 项目
- 多巴胺能神经元 7 项目
- 小鼠胚胎成纤维细胞 1 项目
- 浆细胞 19 项目
- 神经元 200 项目
- 调节性T细胞 69 项目
Show More
Show Less
研究领域
- HIV 3 项目
- 免疫学 56 项目
- 干细胞生物学 39 项目
- 神经科学 1 项目
- 移植研究 3 项目
- 细胞系制备 4 项目
- 脐带血库 1 项目
- 药物发现和毒理检测 9 项目
- 癌症研究 28 项目
Show More
Show Less
产品系列

EasySep™小鼠TIL(CD45)正选试剂盒



沪公网安备31010102008431号